Clinical Trial: Tofacitnib for the Treatment of Alopecia Areata and Variants
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Tofacitnib for the Treatment of Alopecia Areata and Variants
Brief Summary: The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
Detailed Summary: This study is an open-label pilot study. Participants will be treated with oral tofacitinib for a maximum of 5 months. Participants will be evaluated at 3 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects.
Sponsor: Yale University
Current Primary Outcome: Mean Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 3 months ]
Original Primary Outcome:
- Mean Change in Severe Alopecia Tool (SALT) Scores [ Time Frame: 3 months ]SALT score range is from 0 (no hair loss) to 100 (100% hair loss)
- Mean Change in Skindex 16 Socres [ Time Frame: 3 months ]Skindex 16 is a quality of life questionaire with a range of 0-100 wherein 1 is not bothered by the condition and 100 is always bothered by the condition
Current Secondary Outcome: Mean Change in Skindex 16 Scores [ Time Frame: 3 months ]
Original Secondary Outcome:
Information By: Yale University
Dates:
Date Received: July 18, 2014
Date Started: July 2014
Date Completion:
Last Updated: March 31, 2017
Last Verified: March 2017